BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to MDA-MB-468 cell line is 131
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FSTL1 | 3972 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 30336071 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30336071 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs and RT-PCR | NA | 0.48 | 0.5461 | 29249690 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 0.5461 | 34708581 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30262865 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 31604679 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.48 | 0.5461 | 34841239 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 30224376 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 30628646 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 30336071 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 0.7582 | 34708581 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | SFA followed by Western Blotting | NA | 0.48 | 0.7582 | 29750424 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.48 | 0.7582 | 30224376 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs | NA | 0.48 | 0.7582 | 30091683 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by CFA | NA | 0.48 | 0.7582 | 18681906 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs and SP assay | NA | 0.48 | 0.7582 | 31604679 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 30336071 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 0.5695 | 34708581 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 34789263 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 31604679 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.48 | 0.5695 | 34841239 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | qPCR followed by SFA | NA | 0.48 | 0.5695 | 35135840 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.48 | 0.5695 | 30224376 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 30622340 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 30628646 |
| MIR5188 | 43502 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | RT-PCR and IF staining followed by SFA and Migration assay | NA | 0.44 | 0.0011 | 31604679 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Irradiation | CFA followed by Western Blotting and FACs | NA | 0.4 | 0.456 | 34708581 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA and IF staining | NA | 0.4 | 0.456 | 34311079 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by FACs | NA | 0.4 | 0.456 | 34841239 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 35135840 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | MACs followed by SFA | NA | 0.4 | 0.456 | 33845139 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Irradiation | CFA followed by Western Blotting and FACs | NA | 0.4 | 1 | 34708581 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA and IF staining | NA | 0.4 | 1 | 34311079 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | FACs and SP assay followed by SFA and qRT-PCR | NA | 0.4 | 1 | 30572639 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.4 | 1 | 30262865 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.4 | 1 | 30224376 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by FACs | NA | 0.4 | 1 | 34841239 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 1 | 35135840 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | MACs followed by SFA | NA | 0.4 | 1 | 33845139 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.4 | 1 | 34889737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs | NA | 0.4 | 1 | 30091683 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs | NA | 0.4 | 1 | 30191610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | FACs | NA | 0.4 | 1 | 31627418 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | FACs | NA | 0.4 | 1 | 31627418 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by CFA | NA | 0.4 | 1 | 18681906 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 1 | 28817737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 1 | 29249663 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 1 | 29249690 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | FACs followed by SFA | NA | 0.4 | 1 | 29750424 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 1 | 30021199 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.4 | 1 | 31599500 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA and Migration assay | NA | 0.4 | 1 | 31756533 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.4 | 1 | 28817737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.4 | 1 | 28978427 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.4 | 1 | 29895705 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.4 | 1 | 30628646 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | SFA followed by FACs | NA | 0.4 | 1 | 31784862 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs and SP assay | NA | 0.4 | 1 | 31604679 |
| MCL1 | 6943 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting and FACs | NA | 0.4 | 0.0032 | 28978427 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting and FACs | NA | 0.4 | 0.1304 | 28978427 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Western Blotting followed by FACs and SFA | NA | 0.4 | 0.1304 | 28817737 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.1304 | 34789263 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | SFA followed by Western Blotting | NA | 0.4 | 0.1304 | 29750424 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.1304 | 30262865 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.1304 | 31604679 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | qPCR followed by SFA | NA | 0.4 | 0.1304 | 35135840 |
| ABCB1 | 40 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | FACs and SP assay followed by SFA and qRT-PCR | NA | 0.32 | 0.0604 | 30572639 |
| ABCB1 | 40 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.0604 | 31604679 |
| ABCB1 | 40 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.0604 | 31756533 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | FACs and SP assay followed by SFA and qRT-PCR | NA | 0.32 | 0.1739 | 30572639 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.1739 | 34789263 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | SFA followed by Western Blotting | NA | 0.32 | 0.1739 | 29750424 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.1739 | 31604679 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA and qRT-PCR | NA | 0.32 | 0.684 | 34718356 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 34311079 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 34848450 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 35135840 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 35220209 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by ALDEFLUOR assay | NA | 0.32 | 0.684 | 34841239 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by CFA | NA | 0.32 | 0.684 | 18681906 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Bevacizumab | ALDEFLUOR assay followed by Migration and Invasion assay | NA | 0.32 | 0.684 | 31497360 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 28817737 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 28966724 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | ALDEFLUOR assay followed by SFA | NA | 0.32 | 0.684 | 30559934 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs and SFA | NA | 0.32 | 0.684 | 31745977 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by ALDEFLUOR assay | NA | 0.32 | 0.684 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | FACs and SP assay followed by SFA and qRT-PCR | NA | 0.32 | 0.456 | 30572639 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.32 | 0.456 | 30224376 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs | NA | 0.32 | 0.456 | 30091683 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs | NA | 0.32 | 0.456 | 30191610 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | FACs | NA | 0.32 | 0.456 | 31627418 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | FACs | NA | 0.32 | 0.456 | 31627418 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by CFA | NA | 0.32 | 0.456 | 18681906 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.32 | 0.456 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.32 | 0.456 | 29249663 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.32 | 0.456 | 29249690 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.32 | 0.456 | 30021199 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA | NA | 0.32 | 0.456 | 31599500 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA and Migration assay | NA | 0.32 | 0.456 | 31756533 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.32 | 0.456 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.32 | 0.456 | 28978427 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.32 | 0.456 | 29895705 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.32 | 0.456 | 30628646 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | SFA followed by FACs | NA | 0.32 | 0.456 | 31784862 |
| MSI1 | 7330 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.0201 | 29249690 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.6448 | 29249690 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Irradiation | CFA followed by Western Blotting | NA | 0.32 | 0.6448 | 34708581 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Doxorubicin | SFA followed by Western Blotting | NA | 0.32 | 0.6448 | 29750424 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.6448 | 31604679 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | qPCR followed by SFA | NA | 0.32 | 0.6448 | 35135840 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.32 | 0.6448 | 30224376 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.6448 | 30628646 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 34789263 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 31604679 |
| FASN | 3594 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by Western Blotting | NA | 0.28 | 0.0074 | 34841239 |
| FOXM1 | 3818 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | Paclitaxel | Western Blotting and SFA | NA | 0.28 | 0.0053 | 30572639 |
| JUN | 6204 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 31604679 |
| KBM1A | NA | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 31627418 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0891 | 30262865 |
| MET | 7029 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Western Blotting | NA | 0.28 | 0.0191 | 28966724 |
| SNAI2 | 11094 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 31604679 |
| VIM | 12692 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.017 | 31604679 |
| C5 | 1331 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs for CSC marker followed by IF staining | NA | 0.24 | 0.0021 | 35220209 |
| FOXD2-AS1 | 44256 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 30628646 |
| FOXO3 | 3821 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qPCR | NA | 0.2 | 0.0021 | 30224376 |
| ITGA6 | 6142 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.2 | 0.0265 | 34841239 |
| ITGA6 | 6142 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by FACs | NA | 0.2 | 0.0265 | 34889737 |
| NOLC1 | 15608 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.0042 | 34789263 |
| SOX4 | 11200 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.2 | 0.0042 | 34841239 |
| SOX9 | 11204 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0244 | 30622340 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-468 | NA | FACs followed by SFA and Migration assay | NA | 0.12 | 0.211 | 31756533 |